Back to News
Market Impact: 0.2
Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Oppenheimer initiated coverage of Pacira BioSciences (NASDAQGS:PCRX) on September 23, 2026, with an Outperform recommendation. The initiation is a positive analyst signal for the U.S.-based pharmaceutical company, though the article provides no price target, earnings estimates, or additional investment rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PCRX0.45
More News
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- AMD shares are primed for a comeback, says Oppenheimer
- CorMedix stock gains as Heron deal adds four products
- Rezolute at Guggenheim: FDA progress lifts rare-disease hopes
- Hims & Hers earnings up next: Can GLP-1 boom drive profit?